SCHEMBL1869540

SCHEMBL1869540

Cc1cc(-c2cccnc2)cn2c(C=NN(C)S(=O)(=O)c3cccc([N+](=O)[O-])c3)cnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 8/20 0.48
PIK3CD O00329 4/20 0.48
CCNT1 O60563 3/20 0.48
FLT3 P36888 3/20 0.48
CDK9 P50750 3/20 0.48
PIK3CB P42338 3/20 0.47
CDK7 P50613 2/20 0.47
DYRK3 O43781 1/20 0.47
CDK2 P24941 1/20 0.47
CSNK1E P49674 1/20 0.47
CLK1 P49759 1/20 0.47
CLK2 P49760 1/20 0.47
CLK3 P49761 1/20 0.47
GSK3B P49841 1/20 0.47
CDK5 Q00535 1/20 0.47
DYRK1A Q13627 1/20 0.47
MELK Q14680 1/20 0.47
CDK5R1 Q15078 1/20 0.47
DYRK2 Q92630 1/20 0.47
CLK4 Q9HAZ1 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1869539 1.00 PIK3CA (0.48) PIK3CAPIK3CDCCNT1FLT3CDK9
SCHEMBL1871966 0.89 CYP11B1 (0.40) PIK3CAPIK3CDCCNT1FLT3CDK9
SCHEMBL1871967 0.89 CYP11B1 (0.40) PIK3CAPIK3CDCCNT1FLT3CDK9
SCHEMBL1868826 0.88 PIK3CA (0.43) PIK3CAPIK3CDCCNT1FLT3CDK9
SCHEMBL1868827 0.88 PIK3CA (0.43) PIK3CAPIK3CDCCNT1FLT3CDK9
SCHEMBL1865579 0.87 FLT3 (0.42) PIK3CAPIK3CDCCNT1FLT3CDK9
SCHEMBL1865575 0.87 FLT3 (0.42) PIK3CAPIK3CDCCNT1FLT3CDK9
SCHEMBL1867481 0.85 CYP11B1 (0.51) PIK3CAPIK3CDCCNT1FLT3CDK9
SCHEMBL1867484 0.85 CYP11B1 (0.51) PIK3CAPIK3CDCCNT1FLT3CDK9
SCHEMBL1870516 0.85 PIK3CA (0.40) PIK3CAPIK3CDCCNT1FLT3CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8741932-B2 Imidazopyridine derivatives Piramal Enterprises Limited (IN) 2014-06-03 US claimed
US-20120232072-A1 IMIDAZOPYRIDINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-09-13 US claimed
US-8741932-B2 Imidazopyridine derivatives Piramal Enterprises Limited (IN) 2014-06-03 US disclosed
US-20120232072-A1 IMIDAZOPYRIDINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2012-09-13 US disclosed
EP-2496577-A1 IMIDAZOPYRIDINE DERIVATIVES Piramal Life Sciences Limited (IN) 2012-09-12 EP disclosed
WO-2011055320-A1 IMIDAZOPYRIDINE DERIVATIVES PIRAMAL LIFE SCIENCES LIMITED (IN) 2011-05-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232072-A1 IMIDAZOPYRIDINE DERIVATIVES IL6, IL6ST, STAT3 PIK3CA 116/4885PIK3CD 107/4885CCNT1 1243/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.